Its expression has been reported to vary across different cancer types, being downregulated in esophageal cancer [26], upregulated in hepatoblastoma [27] and cervical cancer [28], and positively correlated with head and neck squamous cell carcinoma, particularly in cases with TP53 mutations [29]. This evidence concerns the gene TP53 and cervical carcinoma.